Drug Name: | S-mephenytoin (70989-04-7) |
---|---|
PubChem ID: | 107921 |
SMILES: | CC[C@@]1(C(=O)N(C(=O)N1)C)C2=CC=CC=C2 |
InchiKey: | GMHKMTDVRCWUDX-LBPRGKRZSA-N |
Therapeutic Category: |
Molecular Weight (dalton) | : | 218.256 |
LogP | : | 1.4735 |
Ring Count | : | 1 |
Hydrogen Bond Acceptor Count | : | 2 |
Hydrogen Bond Donor Count | : | 1 |
Total Polar Surface Area | : | 49.41 |
This panel provides information on interacting drugs and their ADRs along with references
Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
---|
This panel provides drug-protein interaction and their ADRs along with references
Toxicity | Interacting Protein | Mechanism | Reference |
---|---|---|---|
Dangerous Side Effects | Cytochrome P450 2B6 (P20813) | Estradiol inhibits CYP2B6 activity@ as a result it increases the level of mephenytoin in blood and causes dangerous side effects [ ADR Type 4 ] | Oxidation of quinidine by human liver cytochrome P-450 |
Dangerous Side Effects | Cytochrome P450 2C19 (P33261) | Ethosuximide inhibits CYP2C19-mediated S-mephenytoin 4#-hydroxylation@ which may increase the level of mephenytoin in blood and cause dangerous side effects. [ ADR Type 4 ] | Safety of anticonvulsants in hepatic porphyrias |
This panel provides drug-food interactions and their ADRs along with references
Food | Toxicity | Reference |
---|
This panel provides information on metabolites and their ADRs along with references
Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
---|
This panel provides information on drug category
Toxicity | Source |
---|